Valuation: KalVista Pharma

Market Cap 1.44B 1.26B 1.16B 1.09B 2.04B 136B 2.08B 13.96B 5.4B 67.02B 5.4B 5.28B 232B P/E 2024
-2.46x
P/E 2025 -5.3x
Enterprise Value 1.42B 1.25B 1.15B 1.08B 2.02B 134B 2.06B 13.81B 5.34B 66.27B 5.34B 5.22B 230B EV / Sales 2024
-
EV / Sales 2025 10.9x
Free-Float
-
Yield 2024 *
-
Yield 2025 -
1 month 23.27
Extreme 23.27
23.39
Current year 23.27
Extreme 23.27
23.39
1 year 23.27
Extreme 23.27
23.39
3 years 23.27
Extreme 23.27
23.39
5 years 23.27
Extreme 23.27
23.39
10 years 23.27
Extreme 23.27
23.39
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 2016-10-31
Chief Executive Officer 61 2024-03-05
President - 2026-06-10
Director TitleAgeSince
Chairman - 2026-06-10

Financials

2024 2025
Net sales - 73.62M 64.55M 59.5M 55.7M 104M 6.94B 107M 715M 277M 3.43B 276M 270M 11.9B
Net income -127M -111M -102M -95.83M -180M -11.95B -183M -1.23B -476M -5.9B -476M -465M -20.47B -164M -144M -133M -124M -233M -15.5B -238M -1.6B -618M -7.66B -617M -603M -26.56B
Net Debt -203M -178M -164M -154M -288M -19.16B -294M -1.97B -763M -9.47B -763M -746M -32.83B -16.01M -14.03M -12.94M -12.11M -22.71M -1.51B -23.18M -155M -60.17M -746M -60.11M -58.79M -2.59B
Logo KalVista Pharma
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company. It has discovered and developed EKTERLY, an oral on-demand treatment for hereditary angioedema (HAE). EKTERLY is formulated as a film-coated tablet for oral administration, with high bioavailability and selectivity for plasma kallikrein, enabling maximal dosing and a rapid decline in edema effectors that cause swelling during an HAE attack. Its clinical trials include KONFIDENT-KID, KONFIDENT-S and KONFIDENT. KONFIDENT-KID is an open-label clinical trial of sebetralstat for on-demand treatment of HAE attacks in pediatric patients. KONFIDENT-KID collects safety, pharmacokinetic and efficacy data for each patient for up to one year and features a proprietary pediatric orally disintegrating tablet formulation of sebetralstat. KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.
Employees
275
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A